ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
In 2021, sacituzumab govitecan (Trodelvy®) was approved by the FDA to treat people with triple-negative MBC. In February 2023, the FDA expanded the approval of the drug for people with HR+, HER2- MBC who have received at least two lines of therapy. As a result, the American Society of Clinical Onoclogy (ASCO) also updated its guidance on the use of this drug.
Read below for more information about this new approval and comments from MBC experts.
Introduction to Sacituzumab Govitecan (Trodelvy®)
Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
- US Food and Drug Administration: FDA Approves Sacituzumab Govitecan (Trodelvy®) for HR+ MBC
- Facing Our Risk of Cancer Empowered (FORCE): Sacituzumab Govitecan (Trodelvy®) in MBC
- Medicine Matters (Video): Hope Rugo, MD: TROPiCS-02 Clinical Trial Shows an Overall Survival Benefit with Sacituzumab Govitecan (Trodelvy®) in HR+, HER2- MBC
- Practice Update: ASCO Guideline Update for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
Sacituzumab Govitecan (Trodelvy®) for Triple-Negative MBC
- National Cancer Institute: Sacituzumab Earns Regular FDA Approval for Triple-Negative MBC
- Targeted Oncology: Lisa Carey, MD: Reviewing the Latest Advancements in Treatment of TNBC
Clinical Trials for Sacituzumab Govitecan (Trodelvy®)
- Metastatic Trial Search: MBC Trials for Sacituzumab Govitecan (Trodelvy®)